In summary, METTL16 acts as a key regulator of OV progression through modulation of MALAT1 and β-catenin signaling, and targeting the METTL16–MAT2A axis may represent a promising therapeutic strategy for ovarian cancer. The gene discussed is MALAT1; the disease is ovarian carcinoma.